world cancer report - iarc

More documents

Recommendations

Info

Infection with S. haematobium is associated with the development of squamous cell carcinoma and in endemic areas, such as Egypt, this type constitutes 90% of bladder tumours [7]. A number of genes which regulate enzymes involved in the metabolism of bladder carcinogens have been identified and it has been hypothesized that subjects carrying specific genotypes could be at an increased risk of bladder cancer [8]. For example, a dominant mutation in the NAT2 gene causes slow metabolism of aromatic amines, favouring their transformation into active carcinogens; slow metabolizers may be at a 40% increased risk of bladder cancer. Similarly, individuals who are null for the GSTM1 gene, which encodes an enzyme involved in the detoxification of polycyclic aromatic hydrocarbons, have been reported to be at increased risk of bladder cancer. There is no evidence for high-penetrance gene mutations that carry an elevated risk of bladder cancer. The oncogene HRAS is mutated at codon 12 in about 40% of bladder tumours. Overexpression of the epidermal growth factor receptor is associated with invasive disease. The gene encoding c-erbB2 (ERBB2) is amplified in a small proportion of bladder tumours. Cytogenetic and molecular techniques have implicated aberration/partial loss of chromosome 9 as a common feature in Cyclin D1 amplification Chromosome 9 LOH TRANSFORMED UROTHELIAL CELL p53 gene inactivation bladder cancer, and the cyclin-dependent kinase inhibitors p16 INK4A and p15 are also implicated in this context. Altered expression of the phosphorylated form of the retinoblastoma protein is common, and most often encountered in invasive tumours. Nuclear overexpression of p53 protein, essentially attributable to mutation of the gene, is common and is associated with disease progression (Fig. 5.86) [9]. Management Most patients with carcinoma in situ progress to muscle invasion within 10 years, but can achieve good responses to intravesical therapy - the administration of a therapeutic agent directly into the bladder, thereby exposing the mucosa to high drug concentrations [10]. The most commonly used agent in intravesical therapy for superficial transitional cell carcinomas, to prevent recurrence, and possibly decrease progression and improve survival, is bacille Calmette-Guérin (BCG), an attenuated strain of the Mycobacterium bovis bacterium which causes tuberculosis. Cytotoxic drugs such as thiotepa, doxorubicin, mitomycin C and/or ethoglucid may be used for superficial tumours to prevent recurrence. The currently preferred treatment for patients with invasive bladder cancer is radical cystectomy. This involves excision VEGF upregulation Cyclin D activation PAPILLARY TRANSITIONAL CELL CARCINOMA “superficial” CARCINOMA in situ (pre-invasive transitional cell carcinoma) p53, RB gene inactivation PDECGF expression Fig. 5.87 Five-year relative survival rates after diagnosis of bladder cancer. of the bladder, prostate and seminal vesicles in males or the bladder, ovaries, uterus, urethra and part of the vagina in females. Urinary diversion, and some restoration of bladder function, may be achieved through a range of reconstruction options that continue to be refined and improved. Adjuvant chemotherapy (e.g with cisplatin, methotrexate and vinblastine, or the latter combination plus doxorubicin) may be employed. Several new agents have been identified [11]. RECURRENT TRANSITIONAL CELL CARCINOMA INVASIVE TRANSITIONAL CELL CARCINOMA Fig. 5.86 Genetic alterations associated with the development of bladder cancer. LOH = loss of heterozygosity, VEGF = vascular endothelial growth factor, PDECGF = platelet derived endothelial cell growth factor. 230 Human cancers by organ site
Partial cystectomy is appropriate for only a minor proportion of patients with invasive bladder cancer. Radical radiation therapy as sole treatment has been evaluated, and criteria contributing to a favourable outcome (tumour size, stage, morphology, REFERENCES 1. Ferlay J, Bray F, Parkin DM, Pisani P, eds (2001) Globocan 2000: Cancer Incidence and Mortality Worldwide (IARC Cancer Bases No. 5), Lyon, IARCPress. 2. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, Lopez-Abente G, Tzonou A, Chang-Claude J, Bolm- Audorff U, Jockel KH, Donato F, Serra C, Wahrendorf J, Hours M, T'Mannetje A, Kogevinas M, Boffetta P (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer, 86: 289- 294. 3. Silverman DT, Morrison AS, Devesa SS (1996) Bladder cancer. In: Scottenfeld D, Fraumeni, FJ eds, Cancer Epidemiology and Prevention, Oxford, New York, Oxford University Press, 1156-1179. 4. Pisani P, Parkin DM, Muñoz N, Ferlay J (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev, 6: 387-400. 5. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Woodman AC (2001) The early detection and diagnosis of bladder cancer: a critical review of the options. Eur Urol, 39: 619-633. 6. Lee R, Droller MJ (2000) The natural history of bladder cancer. Implications for therapy. Urol Clin North Am, 27: 1- 13, vii. etc.) have been determined. Tumour staging is based on the degree to which the tumour has invaded the bladder wall. In more developed countries, five-year relative survival is in the order of 65% (Fig. 5.87), and there has been a steady 7. Noss M, Klotz L (1998) Male urogenital cancer. In: Morris D, Kearsley J, Williams C eds, Cancer: a comprehensive clinical guide, Harwood Academic Publishers, 213- 222. 8. d'Errico A, Malats N, Vineis P, Boffetta P (1999) Review of studies of selected metabolic polymorphisms and cancer. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P eds, Metabolic Polymorphisms and Susceptibility to Cancer (IARC Scientific Publication No. 148), Lyon, IARCPress, 323-393. 9. Brandau S, Bohle A (2001) Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol, 39: 491-497. 10. Metts MC, Metts JC, Milito SJ, Thomas CR, Jr. (2000) Bladder cancer: a review of diagnosis and management. J Natl Med Assoc, 92: 285-294. 11. Maluf FC, Bajorin DF (2001) Chemotherapy agents in transitional cell carcinoma: the old and the new. Semin Urol Oncol, 19: 2-8. improvement during the last decades. Survival is poorer in developing countries, with five-year relative survival rates of 30- 50%. WEBSITE NCI Bladder Cancer Homepage. http://www.cancer.gov/cancer_information/cancer_type/ bladder/ Bladder cancer 231
Page 2 and 3:
WORLD HEALTH ORGANIZATION WHO OMS I
Page 4 and 5:
WORLD CANCER REPORT Editors Bernard
Page 6 and 7:
CONTENTS Foreword 9 1 The global bu
Page 8 and 9:
The global burden of cancer Cancer
Page 10 and 11:
Fig. 1.2 Incidence and mortality of
Page 12 and 13:
Central and Southern Europe differ
Page 14 and 15:
Incidence of cancer in South Centra
Page 16 and 17:
from documentation of disease to a
Page 18 and 19:
TOBACCO SUMMARY >In addition to lun
Page 20 and 21:
Fig. 2.3 Smoking by children is inc
Page 22 and 23:
Cancers positively Sex Standardized
Page 24 and 25:
PHARMACOLOGICAL APPROACHES TO SMOKI
Page 26 and 27:
level the dose—response relations
Page 28 and 29:
lipoprotein-associated cholesterol,
Page 30 and 31:
Agent Cancer site/cancer Main indus
Page 32 and 33:
Industry, occupation Cancer site/ca
Page 34 and 35:
to occupational exposures in develo
Page 36 and 37:
Air pollutant WHO Air Quality Guide
Page 38 and 39:
der cancer of the order of 50% is p
Page 40 and 41:
AFLATOXIN B 1 HEPATITIS VIRUS (chro
Page 42 and 43:
Fig. 2.30 Correlation between regio
Page 44 and 45:
MEDICINAL DRUGS SUMMARY > Certain d
Page 46 and 47:
Drug or drug combination Cancer IAR
Page 48 and 49:
Agent or substance Cancer site/canc
Page 50 and 51:
sources of electromagnetic fields [
Page 52 and 53:
CHRONIC INFECTIONS SUMMARY > Infect
Page 54 and 55:
Infection Subclinical Mutagenic fac
Page 56 and 57:
TUMOURS ASSOCIATED WITH HIV/AIDS Ap
Page 58 and 59:
DIET AND NUTRITION SUMMARY > Up to
Page 60 and 61:
Fig. 2.54 The age-adjusted mortalit
Page 62 and 63:
OVERWEIGHT, OBESITY AND PHYSICAL AC
Page 64 and 65:
IMMUNOSUPPRESSION SUMMARY >Persiste
Page 66 and 67:
Fig. 2.64 Cancer following immunosu
Page 68 and 69:
Syndrome Gene Location Cancer site/
Page 70 and 71:
viduals, confirmation of a gene def
Page 72 and 73:
REPRODUCTIVE FACTORS AND HORMONES S
Page 74 and 75:
PHYTO-ESTROGENS AND CANCER PEVENTIO
Page 76 and 77:
Indicator Number of oral contracept
Page 79 and 80:
Mechanisms of tumour development Th
Page 81 and 82:
The stages in tumorigenesis have be
Page 83 and 84:
PRECURSOR LESIONS IN CHEMOPREVENTIO
Page 85 and 86:
CARCINOGEN ACTIVATION AND DNA REPAI
Page 87 and 88:
adducts, a few weeks or months for
Page 89 and 90:
I Reactive oxygen species Methylati
Page 91 and 92:
which remove the mismatched bases,
Page 93 and 94:
Common human oncogenes Many common
Page 95 and 96:
product of the RB1 gene (pRb) and a
Page 97 and 98:
ates a molecular bridge between p53
Page 99 and 100:
potential cancer genes altered thro
Page 101 and 102:
One of the earliest genes to be ide
Page 103 and 104:
Regulation of the cell cycle and co
Page 105 and 106:
CELL-CELL COMMUNICATION SUMMARY > C
Page 107 and 108:
Connexin genes and tumour suppressi
Page 109 and 110:
APOPTOSIS SUMMARY > The term apopto
Page 111 and 112:
Caspase-8 Caspase-3 c-FLIP Procaspa
Page 113 and 114:
ways. Several options are under inv
Page 115 and 116:
INVASION AND METASTASIS SUMMARY > T
Page 117 and 118:
laminin, entactin and also heparan
Page 119 and 120:
Target Example of agent Comments Ad
Page 121 and 122:
organs, and to respond to local gro
Page 123 and 124:
TOBACCO CONTROL SUMMARY > Tobacco-i
Page 125 and 126:
Region Deaths due to % of total dea
Page 127 and 128:
ipated, is primarily attributable t
Page 129 and 130:
smoke. This may be achieved in part
Page 131 and 132:
there is no evidence for the effica
Page 133 and 134:
industries, processes and occupatio
Page 135 and 136:
stoves arises in rural areas of dev
Page 137 and 138:
Climbing plants on trellis at end r
Page 139 and 140:
HEPATITIS B VACCINATION SUMMARY > P
Page 141 and 142:
Fig. 4.17 Chronic active HBV-associ
Page 143 and 144:
HUMAN PAPILLOMAVIRUS VACCINATION SU
Page 145 and 146:
Vaccine Site of trial Number of pat
Page 147 and 148:
prolonged use. Similar drugs, that
Page 149 and 150:
aspirin and other non-steroidal ant
Page 151 and 152:
SCREENING FOR BREAST CANCER SUMMARY
Page 153 and 154:
Fig. 4.35 Cumulative mortality from
Page 155 and 156:
SCREENING FOR PROSTATE CANCER SUMMA
Page 157 and 158:
Fig. 4.39 Poster designed for an an
Page 159 and 160:
is around 10% for cancer (out of ev
Page 161 and 162:
45 with one positive rehydrated FOB
Page 163 and 164:
eing based on (i) time trends in th
Page 165 and 166:
Fig. 4.48 Women at a clinic in Indi
Page 167 and 168:
SCREENING FOR ORAL CANCER SUMMARY >
Page 169 and 170:
India will provide useful informati
Page 171 and 172:
cer incidence following cure of inf
Page 173 and 174: 100 50 25 10 5 2.5 1 Japan Males Fe
Page 175 and 176: Human cancers by organ site Maligna
Page 177 and 178: tobacco smoking: age at start, aver
Page 179 and 180: diagnosis is usually confirmed by h
Page 181 and 182: is frequent and survival rates are
Page 183 and 184: Fig. 5.14 Physician reading digital
Page 185 and 186: Markers of prognosis in breast canc
Page 187 and 188: cer in the contralateral breast (Ch
Page 189 and 190: 100 50 25 10 5 2.5 1 Japan Chile Po
Page 191 and 192: depends on staging. Small intramuco
Page 193 and 194: Fig. 5.30 A diet rich in fresh frui
Page 195 and 196: ane protein involved in cell adhesi
Page 197 and 198: LIVER CANCER SUMMARY > About 560,00
Page 199 and 200: Fig. 5.39 A woman in the Gambia pre
Page 201 and 202: REFERENCES 1. Ferlay J, Bray F, Par
Page 203 and 204: Certain Possible Uncertain Age Andr
Page 205 and 206: Management The dramatic division be
Page 207 and 208: TUMOUR NORMAL Gastrula PGC 2n Impri
Page 209 and 210: CANCERS OF THE FEMALE REPRODUCTIVE
Page 211 and 212: Fig. 5.62 Five-year relative surviv
Page 213 and 214: Inheritance of high-penetrance gene
Page 215 and 216: invasive malignant. Malignant germ
Page 217 and 218: OESOPHAGEAL CANCER SUMMARY >Cancer
Page 219 and 220: Fig. 5.76 A radiographic view of an
Page 221 and 222: with a stent; laser recannulation,
Page 223: Fig. 5.82 Risk of bladder cancer am
Page 227 and 228: poorly known since hypopharyngeal c
Page 229 and 230: Fig. 5.92 Oral leukoplakia with mil
Page 231 and 232: LYMPHOMA SUMMARY > Malignant lympho
Page 233 and 234: T Fig. 5.101 Nuclear magnetic reson
Page 235 and 236: Fig. 5.106 Five-year relative survi
Page 237 and 238: Fig. 5.109 The immediate aftermath
Page 239 and 240: A B Fig. 5.113 Acute myeloid leukae
Page 241 and 242: Fig. 5.118 Five-year relative survi
Page 243 and 244: Fig. 5.120 Age-specific incidence a
Page 245 and 246: Hereditary condition Mode of inheri
Page 247 and 248: MELANOMA SUMMARY > Approximately 13
Page 249 and 250: Fig. 5.131 Primary melanoma with a
Page 251 and 252: THYROID CANCER SUMMARY > Cancer of
Page 253 and 254: Papillary carcinoma RET/PTC TRK BRA
Page 255 and 256: KIDNEY CANCER SUMMARY > Cancer of t
Page 257 and 258: Stage Clear cell carcinoma Papillar
Page 259 and 260: TUMOURS OF THE NERVOUS SYSTEM SUMMA
Page 261 and 262: ing the optic tract, brain stem and
Page 263 and 264: mut = mutant p53 wt = wildtype p53
Page 265 and 266: SURGICAL ONCOLOGY SUMMARY > Surgica
Page 267 and 268: Year Radical mastectomy (%) Modifie
Page 269 and 270: TELEMEDICINE The prospects for tele
Page 271 and 272: Equipment Energy 50% depth dose App
Page 273 and 274: CANCER EDUCATION IN MEDICAL COURSES
Page 275 and 276:
Fig. 6.10 Crystals of cisplatin: mo
Page 277 and 278:
Responsiveness Cancer (in decreasin
Page 279 and 280:
Most of the world’s most common c
Page 281 and 282:
treatment of cancer. The problems l
Page 283 and 284:
duction. It is clear that tumour ce
Page 285 and 286:
REHABILITATION SUMMARY > Rehabilita
Page 287 and 288:
cer and its associated disability.
Page 289 and 290:
REFERENCES 1. Garden FH, Gillis TA
Page 291 and 292:
Cancer pain relief varies and in so
Page 293 and 294:
EMERGING ISSUES IN PALLIATIVE CARE
Page 295 and 296:
Cancer control The negative impact
Page 297 and 298:
priority to cancer control activiti
Page 299 and 300:
Prevention of cancer Every country
Page 301 and 302:
- Assessing the magnitude of the ca
Page 303 and 304:
high-risk women. Further details on
Page 305 and 306:
ecords departments are either rudim
Page 307 and 308:
THE INTERNATIONAL AGENCY FOR RESEAR
Page 309 and 310:
in the capitals/urban areas of four
Page 311 and 312:
in the overall cancer strategy. WHO
Page 313 and 314:
68% 1955 1975 1995 2025 32% 40% by
Page 315 and 316:
Fig. 7.15 A grandfather at work in
Page 317 and 318:
Fig. 7.17 Main causes of death in d
Page 319 and 320:
Contributors and Reviewers Sources
Page 321 and 322:
Dr Vera Luiz da Costa e Silva Tobac
Page 323 and 324:
Georgia Moore Centers for Disease C
Page 325 and 326:
REVIEWERS Dr Sandra E. Brooks 405 W
Page 327 and 328:
2.53 T. Norat and E. Riboli, IARC 2
Page 329 and 330:
Gastroenterology, 118(2 Suppl 1): S
Page 331 and 332:
5.106 & 5.107 IARC/SEER/Osaka Cance
Page 333 and 334:
4.17 R. Lambert, IARC/Adapted from
Page 335 and 336:
Brain cancer, see nervous system tu
Page 337 and 338:
Fibroblast growth factor (FGF), 117
Page 339 and 340:
Microarray, 240 Micronutrients, 65,
Page 341 and 342:
S Saccharin, 64, 85 Salicin, 153 Sa
show all

world cancer report - iarc

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?